share_log

Gemina Labs Announces Addition to Its IP Portfolio

Gemina Labs Announces Addition to Its IP Portfolio

Gemina Labs宣佈增加其知識產權組合
Accesswire ·  04/09 10:00

VANCOUVER, BC / ACCESSWIRE /April 9, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") today announces that it has licensed a novel biosensing architecture from the University of British Columbia.

不列顛哥倫比亞省溫哥華/ACCESSWIRE /2024年4月9日/ Gemina Laboratories Ltd.(CSE: GLAB)(FRA: 8I7)(“公司” 或 “Gemina”)今天宣佈,它已從不列顛哥倫比亞大學許可了一種新型生物傳感架構。

This licence is the culmination of a programme of research commenced between Gemina and the University of British Columbia in 2021. It lays the foundation for expanding Gemina's technology portfolio to include point-of-care biosensors chips to enable low-cost, high-sensitivity detection of molecular amplification products, small molecules, and proteins. This opens the door to affordable single-use molecular assays for high-sensitivity diagnosis of infections like Mycobacterium tuberculosis with a novel test kit designed to meet the WHO high-priority target product profiles for new tuberculosis diagnostics. This is another step forward for Gemina to help meet the global health challenge to #EndTB2030. The licensed technology is the subject of a new patent application.

該許可證是Gemina和不列顛哥倫比亞大學於2021年啓動的研究計劃的最終成果。它爲擴大Gemina的技術組合奠定了基礎,使其包括即時生物傳感器芯片,以實現對分子擴增產物、小分子和蛋白質的低成本、高靈敏度檢測。這爲經濟實惠的一次性分子檢測開啓了大門,該方法用於對結核分枝桿菌等感染進行高靈敏度診斷,採用一種新的檢測試劑盒,該試劑盒旨在滿足世衛組織對新結核病診斷的高優先目標產品概況。這是Gemina向前邁出的又一步,旨在幫助迎接 #EndTB2030 的全球健康挑戰。該許可技術是新專利申請的主題。

It's a programme of work that's highly consistent with Gemina's strategy of demonstrating that its core technology platform is widely applicable across point-of-care diagnostics, over and above the Company's first focus on improving the performance of lateral flow assays.

該工作計劃與Gemina的戰略高度一致,即證明其核心技術平台廣泛適用於即時診斷,而該公司最初將重點放在改善側流檢測的性能上

Commenting today, Robert Greene, Gemina's CTO, said "One of the great privileges of my role is to be able to partner with exciting researchers at the forefront of their field. Our UBC partnership with Dr. Clifford is an outstanding example of industrial-academic collaboration and we're delighted with the research results that we've been able to achieve, which now form an important addition to Gemina's growing IP-engine".

Gemina的首席技術官羅伯特·格林在今天發表評論時說:“能夠與處於各自領域最前沿的令人興奮的研究人員合作,這是我工作的最大榮幸之一。我們在不列顛哥倫比亞大學與克利福德博士的合作是產學合作的傑出典範,我們對能夠取得的研究結果感到高興,這些結果現已成爲Gemina不斷增長的IP引擎的重要補充。”

On Behalf of the Board of Directors

代表董事會

Brian Firth
CEO
Gemina Laboratories Ltd.

Brian Firth
首席執行官
Gemina 實驗室有限公司

About Gemina Laboratories Ltd.

關於 Gemina 實驗室有限公司

Gemina Labs is a point-of-care diagnostics technology company with a family of transformative, patented, proprietary technologies that power next-generation testing platforms for a wide range of diagnostic targets that affect human health and wellness. Our technology drives testing platforms that are portable, affordable, accurate, and simple to use. Our development pipeline includes proprietary designs for multiple point-of-care diagnostic form factors, including lateral flow assays, biosensors, and molecular assays. Additional information on the Company can be found at

Gemina Labs是一家即時診斷技術公司,擁有一系列變革性、專利的專有技術,爲影響人類健康和保健的各種診斷靶標的下一代測試平台提供支持。我們的技術推動了便攜式、經濟實惠、準確且易於使用的測試平台。我們的開發管道包括針對多種牀旁診斷外形規格的專有設計,包括側流檢測、生物傳感器和分子檢測。有關該公司的其他信息可以在以下網址找到

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

加拿大證券交易所及其監管服務提供商(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Forward-Looking Statements

前瞻性陳述

This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of the Company. Such statements include statements regarding the anticipated terms of any proposed transaction or engagement. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Furthermore, the Company is presently unable to fully quantify the impact that the Covid-19 pandemic will have on its operations and recognizes that certain eventualities may affect planned or assumed performance moving forward. As such, any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.

本新聞稿包括前瞻性信息和陳述,其中可能包括但不限於有關或推斷公司未來業務、運營、財務業績、前景以及其他計劃、意圖、預期、估計和信念的信息和陳述。此類陳述包括有關任何擬議交易或合同的預期條款的陳述。不純粹是歷史事實的信息和陳述是前瞻性陳述。前瞻性信息和陳述涉及假設以及已知和未知的風險、不確定性以及其他因素,這些因素可能導致公司的實際事件、業績、業績或成就與本文前瞻性信息和陳述所表達或暗示的未來事件、業績、業績和成就存在重大差異。儘管公司認爲此處的任何前瞻性信息和陳述都是合理的,但鑑於所使用的假設以及此類信息和陳述中固有的重大風險和不確定性,無法保證任何此類前瞻性信息和陳述會被證明是準確的,因此,建議讀者依賴自己對此類風險和不確定性的評估,不應過分依賴此類前瞻性信息和陳述。此外,該公司目前無法完全量化Covid-19疫情將對其運營產生的影響,並認識到某些可能的情況可能會影響未來的計劃或假設業績。因此,此處的任何前瞻性信息和陳述均截至本文發佈之日作出,除非適用法律要求,否則公司不承擔任何義務,也不打算更新或修改此處的任何前瞻性信息和陳述,也不打算更新實際事件或結果可能或確實與本文任何前瞻性信息和陳述中預測的不同的理由,無論是由於新信息、未來事件或業績還是其他原因造成的適用的法律。

For more information regarding the Company, please contact:

如需了解有關本公司的更多信息,請聯繫:

Gemina Laboratories Ltd
Brian Firth, Chief Executive Officer
Email: investor@geminalabs.com

Gemina 實驗室有限公司
首席執行官 Brian Firth
電子郵件:investor@geminalabs.com

SOURCE: Gemina Laboratories Ltd.

來源:Gemina 實驗室有限公司


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論